Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Preclinical Data on Potential AIDS Immunotherapy Presented ALEXANDRIA, Va., Jan. 27, 1997 -- CEL-SCI Corporation (Nasdaq: CELI/CELIW) announces the presentation of data on its new HGP-30 AIDS immunotherapy product at the Fourth Conference on Retroviruses and Opportunistic Infections in Washington, D.C. The presentation describes preclinical results of CEL-SCI's new heteroconjugate technology combined with the HGP-30 peptide which is currently in clinical studies. It shows that the heteroconjugate peptide attachment technology may eliminate the need for a carrier protein. It is anticipated that the elimination of the carrier protein will simplify and reduce the cost of the manufacturing process. Carrier proteins are often used in vaccines to make antigens more recognizable to the immune system, thereby increasing the immune response. The HGP-30 AIDS vaccine using the carrier protein has been tested in 39 HIV negative individuals. It has been shown in the SCID mice model of human immunity to confer high levels of protection against challenge by a different HIV strain than the one from which HGP-30 is derived. It is also currently in an HIV positive study with 24 patients. HGP-30 differs from other vaccines or immunogen candidates because it is a synthetic copy of a highly conserved part of the p17 core protein of the HIV virus. The heteroconjugate technology combines T-cell binding ligands with small, disease associated, peptide antigens (e.g., HGP-30). The heteroconjugate technology is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections and cancer, when it cannot do so efficiently on its own. Administered like vaccines, heteroconjugates may provide an exciting new class of products to treat and prevent these diseases. CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. In addition to developing the Multikine(TM) cancer treatment and the HGP-30 HIV vaccine, it also is investigating potential vaccines for tuberculosis, malaria and herpes simplex. E-mail this page to a friend or colleague! To print, use this version